



**SINGAPORE O&G LTD.**  
(Company Registration No. 201100687M)

**FOR IMMEDIATE RELEASE**

**SOG POSTS FY 2018 NET PROFIT OF S\$9.1 MILLION ON REVENUE OF S\$34.7 MILLION**

- *Business at O&G and Cancer-related segments continue to grow, accounting for 59.7% and 15.3% of revenue respectively.*
- *Declares a final one-tier exempt dividend of 0.90 Singapore cents and together with interim dividend of 0.80 Singapore cents, brings total dividend payment for FY 2018 to 1.70 Singapore cents*

**Financial highlights for the financial year ended 31 December 2018**

<b>(S\$'000)</b>	<b>FY 2018</b>	<b>FY 2017</b>	<b>Change (%)</b>
Revenue	<b>34,681</b>	29,902	16.0
Profit from operations	<b>13,653</b>	9,869	38.3
Profit before tax	<b>10,931</b>	9,688	12.8
Profit for the period	<b>9,148</b>	8,507	7.5
Basic earnings per share* (Singapore cents)	<b>1.92</b>	1.78	7.9

**SINGAPORE - 15 February 2019 - Singapore O&G Ltd.** (“SOG”, the “Company” or collectively with its subsidiaries, the “Group”), a premier specialist provider in holistic healthcare for women and children, capped off financial year ended 31 December 2018 (“FY 2018”) with a 7.5% increase in net profit to S\$9.1 million on the back of healthy revenue growth of 16.0% to S\$34.7 million.

Excluding a one-off goodwill impairment of S\$2.8 million, and a non-recurring income of S\$0.9 million (net of taxes and associated expenses) during the year, net profit for FY 2018 would have been S\$11.0 million, an increase of S\$2.5 million or 29.4%.

Revenue growth for the year was largely due to higher contributions from the Group’s Obstetrics & Gynaecology (“O&G”) and Cancer-related segments. Accounting for 59.7% of the Group’s business, revenue for O&G segment increased S\$2.7 million to S\$20.8 million, while revenue at Cancer-related segment rose S\$1.5 million to S\$5.3 million.

There was also an increase in revenue contribution of S\$0.8 million to S\$1.0 million in FY 2018 from the Group's new Paediatrics segment which started operations in July 2017. Revenue growth was partially offset by a marginal S\$0.2 million decline from the Group's Dermatology segment.

After providing for tax, net profit rose 7.5% to S\$9.1 million which translates into earnings per share of 1.92 Singapore cents compared with 1.78 Singapore cents in FY 2017. Net assets value per share as at 31 December 2018 stood at 9.35 Singapore cents compared with 9.12 Singapore cents as at 31 December 2017.

For FY 2018, the Group generated a net cash inflow from operating activities of S\$13.4 million, a six-fold increase from S\$2.2 million in FY 2017. This was mainly due to an absence of payment of S\$4.0 million for an acquisition in FY2017 and higher profit before tax as compared with FY 2017.

For the fourth quarter ended 31 December 2018 ("**Q4 2018**"), the Group's revenue increased by S\$0.9 million or 10.6% to S\$8.8 million from S\$7.9 million of the corresponding quarter a year ago ("**Q4 2017**"). The growth was attributed to an increase of S\$0.5 million and S\$0.3 million from O&G and Cancer-related segments respectively, the contribution of S\$0.2 million from the new Paediatrics segment, and partially offset by a marginal S\$0.1 million decline from Dermatology segment.

Net profit for the quarter was S\$23,168 compared to S\$2.0 million in Q4 2017. Excluding the impairment of goodwill of S\$2.8 million, the Group's net profit for Q4 2018 would have been S\$2.8 million, an increase of 39.9% over Q4 2017.

### **Dividend**

In view of the Group's commendable performance in FY 2018, the Board of Directors has recommended a final one-tier exempt dividend of 0.90 Singapore cents per share, which together with the interim dividend payment of 0.80 Singapore cents, brings the total dividend payment for FY2018 to 1.70 Singapore cents, representing 88.6% of the net profit for the year.

Commented Dr. Beh Suan Tiong, Executive Chairman of SOG, "We are pleased to close the year with commendable results and are able to share the rewards with our shareholders. The Group's strategic focus is to continue to expand the depth and breadth of our healthcare services, which we have done so with the commencement of our new Paediatrics business segment in 2017. In 2018, we continue to grow both our Paediatrics and Dermatology segments with the addition of Dr. Christina Ong at Paediatrics and Paediatric Gastroenterology in November 2018 and Dr. Liew Hui Min at the Dermatology practice in December 2018. Both practitioners have vast experience in their respective fields of specialties and we look forward to their contribution to the Group.

Going forward, we will continue to strengthen our four business segments to deliver better results to our shareholders, as well as seeking strategic acquisition opportunities to further expand our healthcare services.”

---

**ABOUT SINGAPORE O&G LTD.**

(“SOG” or collectively with its subsidiaries, the “Group”)

SOG is a leading group of specialist medical practitioners dedicated towards women’s and children’s health and wellness, with a long and established track record in the Obstetrics and Gynaecology (“O&G”) field in Singapore.

The Group is disciplined and focused in delivering a wide range of premier specialist services catering to the medical needs of women and children at affordable prices.

Currently, its spectrum of services include: pre-pregnancy counselling, delivery, pregnancy and post-delivery care, gynaecological and breast cancer, skin and aesthetic treatments, and paediatrics.

As at 31 December 2018, the Group has four operating segments namely: O&G, Cancer-related, Dermatology and Paediatrics with a total of 14 specialist medical practitioners comprising:

- Six O&G Specialists;
- Three Cancer Specialists: One Gynae-Oncologist and two Breast and General Surgeons;
- Three Paediatricians; and
- Two Dermatologists

For more information, please visit SOG’s website at [www.sog.com.sg](http://www.sog.com.sg).

-----  
For media and analyst queries, please contact:

**August Consulting**

Tel: +65 6733 8873

Janice ONG, [janiceong@august.com.sg](mailto:janiceong@august.com.sg)

Avril LIM, [avrillim@august.com.sg](mailto:avrillim@august.com.sg)

---

*This press release has been prepared by the Company and its content have been reviewed by the Company’s Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

*This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Ms. Keng Yeng Pheng, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*